Vertex Pharmaceuticals company profile

VRTX · NASDAQ · USD

Compare Vertex Pharmaceuticals
$537.43Change from previous close: −0.22%Absolute change: −$1.17

Close · November 16, 2026

Company profile

Vertex Pharmaceuticals has 6,400 employees and is headquartered in Boston, United States.

Sales reach patients in the United States, Europe and other countries, with the United States accounting for 62.9% of revenue, Europe for 28.8% and the rest of the world for 8.3%. The biotechnology company offers cystic fibrosis medicines such as TRIKAFTA/KAFTRIO, ORKAMBI and KALYDECO, as well as CASGEVY for sickle cell disease and transfusion dependent beta thalassemia, and JOURNAVX for acute pain in adults. Its pipeline includes candidates for APOL1-mediated kidney disease, type 1 diabetes and myotonic dystrophy type 1. Customers include specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals and clinics.

In the fiscal year ended December 2025, revenue rose 8.9% to $12.0 billion and net income reached $4.0 billion. The company had 6,400 employees at year end and is headquartered in Boston, Massachusetts, where it was founded in 1989.

Company facts

Industry
Biotechnology
Headquarters
50 Northern Avenue, 02210, Boston
Employees
6,400
Chief executive
Reshma Kewalramani
Founded
1989
Fiscal year
January - December
Listing
VRTX · NASDAQ
Currency
USD
ISIN
US92532F1003
Website
vrtx.com

Vertex Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Vertex PharmaceuticalsVRTXUnited States$137.94B6,40037.8%35.0
Regeneron PharmaceuticalsREGNUnited States$98.84B15,41030.4%21.1
ModernaMRNAUnited States$90.38B4,700-80.8%—
argenxARGXUnited States$60.37B1,86331.9%33.3
BeOne MedicinesONCUnited States$47.58B12,00017.8%53.4
Royalty PharmaRPRXUnited States$39.85B10064.4%45.3

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Vertex Pharmaceuticals with its competitors